Natera, Inc.

NTRA Healthcare Diagnostics & Research

Natera, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.3 billion, up 35.9% from fiscal 2024. In the quarter to June 2026, revenue grew 37.7%, EPS grew 36.5%, free cash flow fell 174.0% and total debt was flat, each against the same quarter a year earlier. Revenue growth for five consecutive years, operating cash flow growth for three.

391.98 12.81 −3.16%
Market cap
$58.4B
P/E
0.0×
Fwd P/E
−130×
Dividend yield
—
F-score
6/9
Altman Z
26.84
Beneish M
−2.17
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 0.00 0.00 0.00

+8 more quarters

P/S ratio
14.37 11.32 13.58 10.43
P/FCF ratio
461.93 270.78 287.05 208.20
P/Operating CF
709.82 704.46 423.90 371.85
P/B ratio
21.35 15.95 18.29 17.64
EV/Sales
14.10 11.03 13.27 10.11
EV/EBITDA
0.00 0.00 0.00 0.00
EV/FCF
453.32 263.88 280.55 201.83
Current Ratio
3.00 2.96 3.39 3.27
Net Debt/EBITDA
18.52 13.75 114.60 11.02
Debt/Equity
0.04 0.05 0.05 0.06
Earnings Yield
(0.50%) (0.82%) (0.67%) (1.42%)
Free Cash Flow Yield
0.22% 0.37% 0.35% 0.48%
Free Cash Flow per Share
(0.06) 0.13 0.28 0.27
Book value per Share
12.71 12.54 12.52 9.13
Free Cash Flow
(8.64) 18.03 37.82 36.98
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates